Item 2.02. Results of Operations and Financial Condition. On February 12, 2026, Vertex Pharmaceuticals Incorporated (the "Company") issued a press release in which it reported its consolidated financial results for the three and twelve months ended December 31, 2025. A copy of that press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference. The information set forth in Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
VRTX Vertex Pharmaceuticals Inc / Ma - 8-K
Accession
0000875320-26-0000342.029.01
Item 2.02 - Results of Operations and Financial Condition
Earnings press release item. The actual results are typically in Exhibit 99.1 - fetch may not have completed.
Item 9.01 - Financial Statements and Exhibits
41 words
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Description of Document 99.1 Press Release Dated February 12 , 202 6 . 104 Cover Page Interactive Data File — the cover page XBRL tags are embedded within the Inline XBRL document.